Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ DocMorris Hold (DPA-AFX) +++ DOCMORRIS Aktie +3,41%

FARON Aktie

>FARON Performance
1 Woche: 0%
1 Monat: -7,8%
3 Monate: +3,5%
6 Monate: +5,8%
1 Jahr: +124,2%
laufendes Jahr: +26,9%
>FARON Aktie
Name:  FARON PHARMACEUTICALS OY
Land:  Finnland
Sektor:  Gesundheit
ISIN/ Wkn:  FI4000153309 / A14355
Symbol/ Ticker:  4FR (Frankfurt)
Kürzel:  FRA:4FR, ETR:4FR, 4FR:GR
Index:  -
Webseite:  https://www.faron.com/
Marktkapitalisierung:  315.98 Mio. EUR
Umsatz:  -
EBITDA:  -18.47 Mio. EUR
Gewinn je Aktie:  -0.29 EUR
Schulden:  12.11 Mio. EUR
Liquide Mittel:  9.5 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  - / 161.86 / -
Gewinnm./ Eigenkapitalr.:  - / -
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  FARON
Letzte Datenerhebung:  03.07.25
>FARON Eigentümer
Aktien: 116.95 Mio. St.
f.h. Aktien: 77.63 Mio. St.
Insider Eigner: 32.05%
Instit. Eigner: 9.85%
Leerverk. Aktien: -
>FARON Peer Group

 
02.07.25 - 14:30
 IN BRIEF: Faron Pharmaceuticals Chair Tuomo Patsi adds to shareholding (Alliance)
 
Faron Pharmaceuticals Ltd - Turku, Finland-based developer of cancer immunotherapies - Non-Executive Chair Tuomo Patsi buys 21,500 ordinary shares at €2.435 per share on Monday......
02.07.25 - 12:30
 Faron Pharmaceuticals Ltd: Director Dealing (Accesswire)
 
TURKU, FINLAND / ACCESS Newswire / July 2, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, a......
30.06.25 - 16:12
 Incanthera, Faron Pharmaceuticals, hVIVO, Powerhouse Energy, CleanTech Lithium, ACG Metals - Small Cap Snapshot (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
30.06.25 - 13:27
 Faron Pharmaceuticals Ltd: Director/PCA Dealing (Accesswire)
 
TURKU, FINLAND / ACCESS Newswire / June 30, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, ......
30.06.25 - 10:24
 Incanthera, Faron, hVIVO, Powerhouse Energy, CleanTech, ACG Metals - Small Cap Snapshot (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
30.06.25 - 09:36
 Faron study reveals new mechanism of immune evasion in cancer (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
30.06.25 - 08:30
 Faron Pharmaceuticals: Faron-Supported Research in Theranostics Identifies Secreted Clever-1 as an Independent Driver of Immune Evasion in Cancer, Deepening the Understanding of Bexmarilimab′s Mode of Action (Accesswire)
 
Study details how bexmarilimab treatment reduces circulating sClever-1 in patients with cancer, a key factor in T-cell suppression and PD-1 therapy resistance TURKU, FINLAND / ACCESS Newswire / Jun......
12.06.25 - 08:54
 Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025 (Accesswire)
 
TURKU, FI / ACCESS Newswire / June 12, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancementMed......
05.06.25 - 18:48
 Faron Pharmaceuticals presents promising data at ASCO 2025 conference patients (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
05.06.25 - 17:30
 Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation (Accesswire)
 
TURKU, FI / ACCESS Newswire / June 5, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunot......
02.06.25 - 08:42
 Faron Pharmaceuticals Presents Phase II Data from BEXMAB Study at ASCO 2025 (Accesswire)
 
TURKU, FI / ACCESS Newswire / June 2, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Favorable response rates and survival data in high/very high-risk frontline and r/r MDS support advancemen......
28.05.25 - 03:36
 Poolbeg Pharma, Faron Pharma, Cordiant Digital, Inspired, Imaging Biometrics - Small Cap Snapshot (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
27.05.25 - 08:30
 Faron Pharmaceuticals: Faron′s Bexmarilimab Demonstrates Immune-Activating and Drug-Sensitizing Potential in Myeloid Malignancies (Accesswire)
 
TURKU, FI / ACCESS Newswire / May 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New preclinical data published in Scientific Reports confirms CLEVER-1 inhibition by Bexmarilimab increase......
23.05.25 - 08:31
 Faron Pharmaceuticals: Faron Announces New Data that Highlight Patient Populations with Cancer that are Most Likely to Benefit from First-in-class Immunotherapy Bexmarilimab (Accesswire)
 
TURKU, FI / ACCESS Newswire / May 23, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New data published in the Journal for ImmunoTherapy of Cancerreveals how tumor microenvironment shapes res......
21.05.25 - 16:00
 Faron Pharmaceuticals appoints chief business officer (ShareCast)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
21.05.25 - 13:48
 IN BRIEF: Faron Pharmaceuticals appoints new chief business officer (Alliance)
 
Faron Pharmaceuticals Ltd - Turku, Finland-based developer of cancer immunotherapies - Appoints Ralph Hughes as chief business officer, effective from next Wednesday. Notes Hughes' prior......
21.05.25 - 08:30
 Faron Pharmaceuticals: Faron Appoints Ralph Hughes as Chief Business Officer (Accesswire)
 
Ralph Hughes joins Faron to strengthen Commercial Strategy, Business Development and Market Assessment function TURKU, FI / ACCESS Newswire / May 21, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(Fi......
15.05.25 - 08:30
 Faron Pharmaceuticals: Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress (Accesswire)
 
TURKU, FI / ACCESS Newswire / May 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Overcoming immune resistance in HR-MDS: Detailed safety and efficacy Phase II data on bexmarilimab to be p......
14.05.25 - 15:42
 Faron Pharmaceuticals Ltd: Grant of Options (Accesswire)
 
TURKU, FINLAND / ACCESS Newswire / May 14, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN):Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company fo......
12.05.25 - 08:30
 Faron Pharmaceuticals Presents Promising Phase 1/2 Data from BEXMAB Study at MDS 2025 Plenary Session (Accesswire)
 
TURKU, FI / ACCESS Newswire / May 12, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - BEXMAB data highlights meaningful clinical benefit, with beneficial immunological and hematological impact......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der guckt die Bälle weg. - Fritz Walter
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!